Diabetes Self-Management Blog

Late last week, results from several European studies showing a possible link between Lantus (insulin glargine) and cancer were published online in the journal Diabetologia. Health agencies such as the U.S. Food and Drug Administration (FDA) and the International Diabetes Federation (IDF) have been swift in their response to the release of this information, indicating that the studies are not conclusive and that people with diabetes should not stop taking Lantus without speaking to their doctors.

The first of the studies in question, from Germany, involved 127,031 people with diabetes who used insulin; it found that cancer was more common in people using Lantus than in those prescribed a comparable dose of human insulin. Subsequent to this study, additional research into the subject was carried out using information from patient databases. A study from Sweden looked at 114,841 people being treated with insulin, and found that those using only Lantus were almost twice as likely to be diagnosed with breast cancer. Research from Scotland, which included 49,197 people with diabetes on insulin therapy, also found that people taking only Lantus were more likely to have cancer. However, this finding did not achieve statistical significance. (A result is statistically significant if it is unlikely to have occurred by chance.) A final study from the United Kingdom that involved 10,067 people with diabetes did not find a link between the use of Lantus and the development of cancer.

On June 26, the American Diabetes Association issued a statement “caution[ing] against overreaction until more information is available.” And the FDA recently cast doubt on the research findings, saying that the studies may have been too short to assess whether a cancer risk does in fact exist with the use of Lantus. The European Association for the Study of Diabetes has requested further study into the matter.

For more information, see the published papers on Diabetologia’s Web site, the IDF’s official statement on the situation, and the article “Lantus Insulin: A Possible Link with Cancer — Requires Further Investigation.”


We are currently experiencing technical difficulties with our commenting system. Thank you for your patience as we work to resolve them.

Insulin & Other Injected Drugs
New Weekly Type 2 Diabetes Drug Approved (09/26/14)
Dispelling the Myths of Insulin Therapy (08/01/14)
Insulin for Type 2 (07/14/14)
FDA Approves Inhalable Insulin (07/03/14)

Diabetes Research
A Diabetes Cure in Mice (11/13/14)
Mediterranean Diet May Benefit Kidneys (11/06/14)
Can Grapefruit Juice Prevent Weight Gain, Increase Insulin Sensitivity? (10/16/14)
Low-Carb Diet Improves Quality of Life in Type 2 Diabetes (10/07/14)

Diabetes News
Mediterranean Diet May Benefit Kidneys (11/06/14)
New Metformin Combination Medicine Approved for Type 2 Diabetes (10/30/14)
FDA Approves Remote Glucose-Monitoring Technology (10/24/14)
Can Grapefruit Juice Prevent Weight Gain, Increase Insulin Sensitivity? (10/16/14)

Diane Fennell
A Gram of Turmeric a Day to Keep Dementia At Bay? (11/20/14)
Some Sulfonylureas May Be Safer Than Others (11/14/14)
Mediterranean Diet May Benefit Kidneys (11/06/14)
New Metformin Combination Medicine Approved for Type 2 Diabetes (10/30/14)



Disclaimer of Medical Advice: You understand that the blog posts and comments to such blog posts (whether posted by us, our agents or bloggers, or by users) do not constitute medical advice or recommendation of any kind, and you should not rely on any information contained in such posts or comments to replace consultations with your qualified health care professionals to meet your individual needs. The opinions and other information contained in the blog posts and comments do not reflect the opinions or positions of the Site Proprietor.